docetaxel

P2, N=143, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: May 2027 --> Nov 2027 | Trial primary completion date: Jul 2026 --> Dec 2026

These findings establish selective CDK4 inhibition as a therapeutically active and mechanistically rational strategy in prostate cancer and support AU2-94 as a candidate for further preclinical and clinical development, including in combination regimens for advanced and therapy-resistant disease.

In TRITON3, rucaparib improved radiographic progression-free survival (rPFS) over physician's choice of therapy (docetaxel or a second-generation androgen-receptor pathway inhibitor [ARPI]). For patients with BRCA mutations, rucaparib offers a targeted oral alternative to chemotherapy that can delay mCRPC progression while reducing many of the logistical, physical, and clinical burdens commonly associated with chemotherapy. Its oral administration and flexible dosing enable an individualized approach that reduces treatment interruptions and maximizes clinical benefits.

In PC-3 cells, upregulation of FOXO3 significantly inhibited vimentin expression and promoted E-cadherin expression, as well as enhanced cell sensitivity to docetaxel...Consistently, the in vivo experiments further confirmed the cancer inhibitory role of LINC00222 in prostate cancer. The present study revealed that LINC00222 adsorbed miR-19a to modulate FOXO3/APC/β-catenin signaling cascades and thereafter inhibited prostate cancer progression, which provided valuable insights into prostate cancer treatment.

P=N/A, N=100, Active, not recruiting, Bayer | Trial primary completion date: Jul 2026 --> Mar 2026

Among patients with heavily pretreated and immunotherapy-exposed recurrent or metastatic NPC, becotatug vedotin significantly improved ORR and PFS compared with chemotherapy, with comparable toxicity and encouraging but immature OS results.

This ADP-ribosylation-based prognostic model reliably predicts LUAD survival and identifies potential biomarkers for tailored therapy.

P2, N=39, Recruiting, University of Chicago | Not yet recruiting --> Recruiting

Our study suggests that miR-4295 has the potential to be a therapeutic target for gastric cancer by targeting BCL2L11 to function as an oncogenic miRNA in gastric cancer. However, there are still many issues that need to be addressed. More research is required to find the optimal strategy and schedule for down-regulating miR-4295, as well as to determine the most feasible method for delivering this system to tumor cells. In summary, down-regulating miR-4295 is a promising strategy for reversing chemotherapy resistance, but more research is needed to clarify the above issues.

Furthermore, fenofibrate exhibits synergistic effects with conventional chemotherapeutic agents (e.g., paclitaxel and docetaxel) by enhancing T-cell viability, activating immune responses, and thereby improving chemotherapy sensitivity. This review comprehensively summarizes the efficacy and underlying mechanisms of fenofibrate against diverse cancer types and discusses the potential applications and challenges associated with its repurposing for cancer therapy. A deeper understanding of fenofibrate's anti-cancer capabilities and molecular targets may provide novel insights for the development of innovative therapeutic strategies.

Notably, the therapeutic effect was comparable to that of docetaxel, a current standard-of-care chemotherapy, without noticeable side effects on body weight, proximal aorta or heart function detected in immune-deficient mice. These findings suggest that targeting TβRI cleavage using specific mAbs is a novel precision medicine approach for the treatment of mCRPC. By selectively blocking the prometastatic activity of TβRI-ICD without disrupting physiological TGFβ signaling, this strategy may provide a safer and more effective alternative to existing therapies for advanced prostate cancer.

P3, N=440, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting